Uses of undefined

Letermovir is used for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT). It is also used for the prophylaxis of CMV disease in adult kidney transplant recipients who are at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).

undefined Drug administaration and Dosage available

Letermovir is used for CMV prophylaxis in HSCT and kidney transplant recipients, with administration either orally or via IV infusion. If administered intravenously, it will be given by a healthcare professional in a hospital setting through a sterile 0.2 or 0.22 micron filter. If co-administered with cyclosporine, dosage adjustments may be needed. For specific dosing instructions, consult your healthcare provider.

Warnings, Precautions and Side Effects of undefined

Warnings

• Risk of Drug Interactions: Concomitant use with certain drugs can cause significant interactions, leading to adverse reactions or reduced effectiveness of either Letermovir or the other drugs.
• Consider Drug Interactions: Review and monitor concomitant medications during Letermovir therapy. Consider potential drug interactions before and during treatment.
• Impact on Transporters and Enzymes: Letermovir is a substrate of OATP1B1/3, P-glycoprotein (P-gp), and UGT1A1/3 enzymes. Using it with inhibitors of these transporters can increase its plasma concentrations.
• Cyclosporine Interactions: The drug interaction effects may differ when co-administered with cyclosporine. Refer to the prescribing information for cyclosporine for further details.

Precautions

Monitor for potential drug interactions during treatment with Letermovir, especially when co-administered with inhibitors or inducers of transporters and enzymes. Adjust the dose if used with cyclosporine or other interacting medications. Carefully review all concomitant medications to prevent adverse reactions and ensure optimal efficacy. Always consult your healthcare provider before starting Letermovir therapy.

Side Effects

Side effects are unwanted symptoms caused by medicines. Although all drugs can cause side effects, not everyone experiences them.

Common side effects of Letermovir:

• Nausea
• Cough
• Diarrhea
• Headache
• Vomiting
• Tiredness
• Swelling in arms and legs
• Stomach (abdominal) pain

Serious side effects of Letermovir:

• Severe allergic reactions (e.g., rash, itching, difficulty breathing)
• Liver problems (e.g., yellowing of the skin/eyes, dark urine)
• Severe gastrointestinal issues

Word Of Advice

Always follow your healthcare provider’s instructions regarding dosage and administration, especially when using Letermovir alongside other medications. Inform your doctor about all the medicines you are taking to avoid potential drug interactions. Regular monitoring may be required to ensure the treatment is working effectively and to detect any side effects early. If you experience any unusual symptoms or side effects, contact your healthcare provider promptly.

Frequently Asked Question

• What is the drug letermovir used for? 
• Letermovir is used to prevent cytomegalovirus (CMV) infection and disease in adult patients who have received a stem cell or kidney transplant. It helps reduce the risk of CMV reactivation in these high-risk individuals.

• Can letermovir be cut in half?
• It is not recommended to cut letermovir tablets in half unless advised by your healthcare provider. Doing so may affect the dose and effectiveness of the medication. Always follow your doctor's instructions for proper administration.

• How long is letermovir given for?
• Letermovir is typically given for 100 to 200 days, depending on the type of transplant and the patient's risk of CMV infection. Your healthcare provider will determine the exact duration based on individual needs.

• Does letermovir treat CMV?
• Letermovir does not treat active CMV infection but prevents CMV infection and disease. It is used to prevent CMV reactivation in patients at high risk, such as those who have received a stem cell or kidney transplant. It helps reduce the likelihood of developing CMV-related complications.

• Is letermovir approved by the FDA?
• Yes, letermovir is approved by the FDA. It received approval on 8th November 2017 for the prevention of CMV infection in transplant patients.